RIKEN chemists have come up with a simple way to add a radioactive element to an antibody and have demonstrated that this produces a potent weapon against tumors in mice.
Tumor-targeting therapy is sometimes referred to as ‘missile therapy’ by researchers in Japan, says Katsunori Tanaka, who heads the RIKEN Biofunctional Synthetic Chemistry Laboratory (BSCL). That’s because two components are needed: a guided missile and a warhead. In the case of radiotherapy, the warhead is a radioactive isotope that kills tumors by subjecting them to high doses of radioactivity.
Most isotopes used in radiotherapy are beta-particle emitters—that is, they give off electrons when they decay. But alpha-particle emitters, which release helium nuclei consisting of two protons and two neutrons, are much preferred since alpha particles are more than 7,000 times more massive than electrons. As a result, they travel far shorter distances before stopping, thereby minimizing collateral damage to healthy cells near a tumor.
But Tanaka notes there are two problems to using alpha-particle emitters in radiotherapy: producing alpha-particle emitters and then chemically attaching them to antibodies. Now, he and his colleagues have overcome both problems.
To make an alpha emitter, Tanaka and Katsumasa Fujiki, also at BSCL, teamed up with physicists at the RIKEN Nishina Center for Accelerator-Based Science to use its world-class cyclotron facility to produce astatine-211.
They then used a reaction they had previously developed, the RIKEN click reaction, to attach astatine-211 to antibodies to target skin cancer cells. The reaction is very attractive, having many advantages over conventional reactions. “Since it is a ‘one-pot’ reaction you don’t have to make each reaction, sequence of the reactions, and isolate each compound and then go to the next step,” says Tanaka. “We just take the components we need and mix them together.”
Furthermore, the RIKEN click reaction can be performed under mild conditions, which is important since the harsh conditions of conventional reactions can destroy antibodies.
The RIKEN click reaction was crucial for combining astatine-211 to antibodies, Tanaka notes. “The RIKEN click reagents just go to the surface locations of the antibodies—they don’t react indiscriminately with all sites on the antibody,” he says. “This ensures that the antibody retains its activity.”
With help from colleagues at the RIKEN Center for Biosystems Dynamics Research, the researchers demonstrated the effectiveness of their compound by using it to target skin cancer tumors in mice. They showed that it accumulated at tumors and suppressed their growth.
The team intends to investigate other vehicles for conveying astatine-211 to tumors such as glycoclusters. They are also keen to partner with medical researchers to bring the therapy to patients.